

## Zomacton® (somatropin) - New indications

- On July 19, 2018, Ferring announced the FDA approval of Zomacton (somatropin), for the treatment of pediatric patients with short stature associated with Turner syndrome; idiopathic short stature, height standard deviation score ≤ -2.25 and associated with growth rates unlikely to permit attainment of adult height in the normal range; short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency; and short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years of age.
- Zomacton is also approved for the treatment of pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone (GH); and for the replacement of endogenous GH in adults with GH deficiency.
- The approval of Zomacton's new indications were based on one long-term, open-label trial in patients with Turner syndrome; two placebo-controlled trials and 1 dose-response study in patients with idiopathic short stature; a 2-year, open-label study in patients with SHOX deficiency, and a 2-year, open-label trial in patients with SGA.
  - Refer to the Zomacton drug label for further information about the clinical studies.
- The recommended subcutaneous (SC) dose of Zomacton should be individualized for each patient based on the growth response.

Population	Indication	Dosage Regimen
Pediatric	GH deficiency	0.18 mg/kg/week – 0.3 mg/kg/week
	Turner syndrome	Up to 0.375 mg/kg/week
	Idiopathic short stature	Up to 0.37 mg/kg/week
	SHOX deficiency	0.35 mg/kg/week
	SGA	Up to 0.47 mg/kg/week
Adults	GH deficiency (non-weight based approach)	Approximately 0.2 mg/day and increase every 1 to 2 months by ~0.1 mg/day to 0.2 mg/day according to individual patient requirements
	GH deficiency (weight based approach)	0.006 mg/kg daily and increase according to individual patient requirements up to a maximum of 0.0125 mg/kg/day

- In pediatric patients, divide the calculated weekly dose of Zomacton into equal doses and administer SC either 3, 6, or 7 days per week.
- In adult patients, administer the prescribed dose of Zomacton daily.
- Therapy with Zomacton should be supervised by a physician who is experienced in the diagnosis and management of patients with the conditions for which Zomacton is indicated.
- Refer to the Zomacton drug label for additional dosing information.
- In September, Zomacton will be available to use with the ZOMA-Jet 10 Needle-Free Delivery System.



## optumrx.com

OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.